Trust Stamp Files U.S. Provisional Patent for LLM-Based MDAS, Pilot Launch Q1 2027
IDAI•Trust Stamp filed U.S. Provisional Patent No. 64/091,057 on June 15, 2026 for its MDAS, its first LLM-focused AI patent, bringing its total to 27 issued and seven pending patents. MDAS tokenizes patient identities and uses three-model consensus to flag bias and hallucinations, with pilot slated for Q1 2027.
1. Provisional Patent Filing
On June 15, 2026 the company filed U.S. Provisional Patent Application No. 64/091,057 entitled “Medical Diagnostic Assurance System,” marking its first LLM-focused AI patent and adding to its portfolio of 27 issued and seven pending patents across AI, biometrics and cryptography.
2. MDAS System Features
MDAS is designed as a self-contained sovereign system that tokenizes patient identities to secure records and employs a three-model consensus to challenge or reinforce medical practitioner diagnoses, aiming to reduce confirmation bias amplification and hallucinations without providing primary diagnoses.
3. Pilot Program and Timeline
The company is negotiating a pilot program with qualified medical practitioners and aims to deploy MDAS in Q1 2027, positioning the technology for testing ahead of potential commercial rollout.
